SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is drawing attention around hopes for a recovery and a breakout from a prolonged trading range, with traders pointing to rising volume and repeated resistance tests. Bulls anticipate a short squeeze, while skeptics cite weak price action and warn that the token could keep falling; no specific catalyst is established.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention around Starknets Bitcoin DeFi and privacy push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are pairing those themes with recent price and volume strength, while some remain cautious about token unlocks and volatility.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is drawing attention amid a technical rebound and breakout attempts, with traders pointing to elevated short interest and speculating that covering could add buying pressure. Bulls see a turnaround and renewed enterprise AI demand, while skeptics remain focused on declining revenue and ongoing losses.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

AERO is drawing attention amid a rebound and anticipation of the AerodromeVelodrome merger and broader multi-chain rollout, which traders see as an expansion beyond Base with potential to increase liquidity and fee activity. Sentiment is largely bullish, though some traders question whether the move can hold and worry about a pullback or sell-the-news reaction.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs privacy-enabled perpetuals launch with Hyperliquid is a prominent catalyst, with traders linking it to the tokens sharp rally. The discussion is broadly bullish on NEARs AI-agent and cross-chain infrastructure, though some traders warn of a pullback after the rapid gains.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile ambitions have fueled fears that it could eventually compete with T-Mobile and other U.S. carriers, prompting a sharp selloff in telecom shares. Traders are divided between viewing the move as a meaningful long-term competitive threat and calling the reaction excessive because building a rival network would require substantial infrastructure and time.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

LUNC is drawing attention amid renewed speculation about token burns and supply reduction, including anticipated Market Module 2.0 changes and a possible USTC repeg, alongside broader Terra ecosystem development chatter. Bulls see a comeback setup, while skeptics point to the large supply, weak liquidity and limited follow-through; these catalysts remain uncertain.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is drawing attention over sharply reduced monthly distributions and a persistently weak share price, with holders debating whether Bitcoins recovery can revive payouts. Some frustrated investors are considering selling, while others are accumulating in anticipation of a BTC rebound; no listed article directly verifies this discussion.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta Personals launch and rollout of fiat-payment features, including ACH access and Visa Direct/Bivo Cash integrations, have drawn attention to KTA. Bulls view the releases as a step toward real-world adoption, while skeptics say the price response and limited demonstrated network usage leave execution unproven.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Discussion centers on reported Google Cloud validation of Rezolves data technology and SQDs role in blockchain indexing, alongside claims of Robinhood network use and growing data activity. Bullish traders see enterprise adoption as support for SQDs infrastructure thesis, while skeptics question whether those developments translate into value for the token and point to volatility and token supply concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strong Q1 growth and record quarterly revenue and EBITDA are driving bullish discussion, alongside interest in Shilpa Medicares formulations and biologics pipeline. Traders are also weighing regulatory and product-quality developments, including a USFDA inspection with one procedural observation and a voluntary Class II recall of chemotherapy vials.

Shilpa Medicare Limited India Switzerland United States of America

SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

SteinCares, Shilpa strike Latin America biosimilar licensing pact

Costa Rica-based specialty healthcare company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals, part of Shilpa Medicare, to commercialize a biosimilar across Latin America.

Shilpa Medicare Limited - 11/21/2025

Shilpa Medicare Limited - 11/21/2025. Country: India. Record Type: 483

Lupin, 3 other pharma stocks in focus after important inspections at their units. Do you own?

Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility.

Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices

RAICHUR, India , Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis , the world's most trusted provider of business sustainability ratings. The company achieved an exceptional score of 82/100 , placing it in the 98th percentile globally among 130,000 + companies evaluated by EcoVadis. This performance underscores our industry-leading Environmental, Social and Governance (ESG) practices and reflects our long-term commitment to building a responsible, resilient, and sustainable pharmaceutical enterprise. EcoVadis assesses organizations on four key pillars — Environment, Labor & Human Rights, Ethics, and Sustainable Procurement — and this recognition positions Shilpa Pharma Lifesciences among the top few global companies rated for sustainable business operations. Speaking on this milestone, Mr. Keshav Bhutada , ED & CEO of Shilpa Pharma Lifesciences emphasized that "Sustainability and innovation are integral to Shilpa's CDMO growth strategy to work with global innovator companies for their New chemical Entity programs.

Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India , Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successful completion of its fourth complex clinical program SMLINJ011 , with positive topline Phase 3 results for Shilpa's OERIS™ (Ondansetron Extended-Release Injection) —an innovative formulation designed to improve prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This milestone underscores Shilpa's growing leadership in differentiated drug-delivery systems and oncology supportive-care therapeutics , reflecting the company's commitment to advancing patient-centric innovation. Study Overview A Phase III, multicenter, randomized, double-blind, non-inferiority trial was conducted across multiple oncology centers in India to compare OERIS™ with conventional ondansetron injections in 240 patients receiving moderately or highly emetogenic chemotherapy.

Blood donation camp held on birthday

Raichur: KH Honneshaiah, head of operations at Shilpa Medicare, emphasised the importance of blood donation, stating that it has the potential to save.

Trading Radar For August 14: ICICI Bank, Infosys, Muthoot, IRCTC, RVNL, Shilpa Medicare, And Zydus Are On Stocks Watchlist

Equity

IOC, Vodafone Idea, Glenmark Pharma, and AstraZeneca Pharma, among others, are expected to post their quarterly earnings today. JSW Cement to list at 10 am.

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 14 August 2025

Sumeet Bagadia recommends five breakout stocks to buy today: Gujarat Apollo Industries, Vimta Labs, Skipper Ltd (India), Indian Metals and Ferro Alloys, and Shilpa Medicare.

Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA delivers a novel dual-action mechanism, combining anti-inflammatory benefits with enhanced bile acid regulation. This innovative therapy promises to halt the progression of NAFLD to severe liver conditions such as NASH, cirrhosis, and liver failure. Clinically Proven and Safe: Robust clinical trials demonstrate NorUDCA's significant superiority over placebo in efficacy, with an excellent safety profile and no major adverse events reported RAICHUR, India , Aug. 14, 2025 /PRNewswire/ -- In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg , the first-ever approved therapy targeting NAFLD.

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical products and wind power generation. Its products include oral solids, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. The company was founded on November 20, 1987, and is headquartered in Raichur, India.

Current Price	1,025.70
Prev Close	1,028.00
Open	1,025.40
Dividend Yield	0.17%
50-Day Moving Average	919.81
Beta	0.13
Avg. Volume	1.02M
PE Ratio	67.21

52-Week High	1,095.00
52-Week Low	259.50
Market Capitalization	199.56B
EPS (Annual)	12.44
Price to Book	7.71
Revenue Per Employee	13.59M

Feed

News

Sentiment

Fundamentals

Info

SHILPAMED.NSE Fundamentals